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Phenotype and management of patients
with familial adenomatous polyposis in
Hong Kong: perspective of the Hereditary
Gastrointestinal Cancer Registry
Objectives. To report on the phenotypic spectrum and clinical management of
Chinese patients suffering from the rare autosomal dominant colorectal cancer
syndrome of familial adenomatous polyposis.
Design. Analysis of prospectively collected data from the database of a regional
registry.
Setting. The Hereditary Gastrointestinal Cancer Registry, Hong Kong.
Participants. One hundred and eight patients with proven familial adenomatous
polyposis from 36 local Chinese families with the condition recruited to the
Registry from 1995 to 2001.
Interventions. Screening programme for at-risk family members, prophylactic
surgery at presymptomatic diagnosis, and surveillance programme for extracolonic
lesions in affected individuals.
Main outcome measures. Rate of colorectal cancer, type of surgical treatment,
spectrum of extracolonic lesions, and management of the syndrome.
Results. Fifty patients suffered from colorectal cancer with a mortality rate of
78.0%. The strategy of presymptomatic diagnosis by screening and appropriate
prophylactic surgery reduced the incidence of colorectal cancer. Affected indi-
viduals were prone to develop potentially serious extracolonic lesions including
thyroid cancer (5.7%), desmoid tumour (15.7%), gastroduodenal adenomas
(7.1%), duodenal microadenoma (17.1%), and pouch polyposis (17.4%).
Conclusions. Screening and prophylactic surgery are effective ways to prevent
colorectal cancer for patients with familial adenomatous polyposis. Lifelong
regular surveillance is necessary to detect and manage extracolonic lesions. A
dedicated registry is essential to coordinate clinical management and to compile
data for furthering knowledge of this rare but complex syndrome.
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Introduction
Familial adenomatous polyposis (FAP) is one of two heredi-
tary colorectal cancer syndromes. It is an autosomal domin-
ant condition with an estimated frequency in the popu-
lation of 1 in 10 000 and a penetrance rate of almost
100%.1 This condition accounts for 1% of all colorectal
cancers.2-4
Affected individuals are healthy at birth. During the
second or third decade of life, however, adenomatous
polyps begin to develop until the colon and rectum are
covered by hundreds or thousands of growths.5 If left
untreated, one or more of these polyps will inevitably
develop into colorectal adenocarcinoma at a mean age of
40 years.6,7 Offspring of an affected individual will have a
50% chance of inheriting and developing the disease.
Presymptomatic diagnosis by screening of at-risk first-
degree relatives and prophylactic proctocolectomy are
effective ways to prevent malignant transformation, and
thus reduce mortality and morbidity from colorectal
cancer. Apart from colorectal involvement, patients with FAP
are at risk for a broad spectrum of extracolonic manifest-
ations (ECMs) involving all three embryonic cell lineages.
Some ECMs, including epidermoid cyst, osteoma, dental
odontoma, and gastric fundic gland polyps, have benign
courses. Certain ECMs have, however, potentially life-
threatening consequences. Upper gastrointestinal malignan-
cies (especially ampullary adenocarcinoma) and desmoid
tumours represent the two major causes of morbidity and
mortality after prophylactic colectomy for patients with
FAP. Therefore, regular surveillance for ECMs is recom-
mended. Familial adenomatous polyposis is also associated
with a variety of other malignancies including pancreatic,
biliary tree, small intestine, thyroid, adrenal, and brain
tumours.
Clinical management of families with FAP requires a
multidisciplinary approach and is best achieved by a
dedicated registry. The first FAP registry was established in
1925 by Lockhart-Mummery.8 In Hong Kong, the Heredi-
tary Gastrointestinal Cancer Registry was established in
1995 with the aim of achieving secondary colorectal cancer
prevention for high-risk families through early detection,
timely treatment, education, and ongoing research. One of
the service targets is families affected by FAP in Hong Kong.
The aims of this paper are to report on the phenotypic
manifestations of the local population with FAP and to
discuss the clinical management of individuals with this
rare syndrome.
Methods
The Hereditary Gastrointestinal Cancer Registry, based
at Queen Mary Hospital, accepts voluntary referrals of
families with FAP throughout Hong Kong, both by medical
practitioners in the private and public sectors and by
self-referral of affected families. Upon referral, pedigrees
(family trees) are established by obtaining family histories
from patients and their relatives during face-to-face and
telephone interviews. These interviews are conducted by a
trained Registry coordinator. From the pedigrees, family
members at risk of inheriting the condition are identified.
Medical records of patients with FAP are traced from
the referral hospitals or from the hospitals where patients
underwent investigation and treatment. Relevant clinical data
are entered into the Registry database. Regular endoscopic
surveillance is arranged after colectomy (Box 1). A genetic-
guided screening programme is offered to at-risk family
members (Box 2). New patients with FAP identified by the
screening programme are referred to a specialist surgical
unit for operative treatment and regular surveillance. Data
presented in this paper were obtained from the Registry
database. Statistical analysis was performed by Statistical
Package for Social Science (Windows version 10.1; SPSS
Inc., Chicago, United States).
Results
From November 1995 to July 2001, the Hereditary
Gastrointestinal Cancer Registry recruited 36 Chinese fam-
ilies with FAP. Eighteen (50.0%) of these families were
referred from Queen Mary Hospital where the Registry was
based; 11 (30.6%) were referred from other public hospitals;
two (5.6%) were referred from private practitioners; and five
(13.9%) were self-referred.
From pedigree analysis, 108 patients with FAP were
identified from these 36 families—59 were male and 49 were
female. The median number of patients with FAP from each
family was 2 (range, 1-19; standard deviation [SD], 3.3).
At recruitment, 15 patients from separate families reported
no history of FAP in other family members, suggesting
Box 2. Genetic-guided screening programme for a family
with familial adenomatous polyposis
(1) Detection of pathogenic mutation from the blood of a
surviving index patient
(2) If the mutation is known, genetic testing will be offered to
at-risk family members older than 12 years
(a) Flexible sigmoidoscopy will be offered biennually to
members found to carry the mutated gene. When
polyps develop, prophylactic surgery will be arranged
(b) Further screening will be discontinued for members who
do not carry the mutated gene
(3) If the mutation cannot be identified, all at-risk family
members will be offered flexible sigmoidoscopy biennually
until they reach the age of 50 years or until polyps develop,
whichever comes first
Box 1. Endoscopic surveillance programme for patients with
familial adenomatous polyposis after prophylactic colectomy
(1) Flexible sigmoidoscopy every 6 months after total abdominal
colectomy and ileorectal anastomosis
(2) Pouchoscopy every 2 years after proctocolectomy and ileal
pouch anal anastomosis
(3) Upper endoscopy and duodenoscopy every 2 years for all
patients
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spontaneous mutation at a rate of 41.7%. One hundred and
seventy-seven family members with a 50% risk of inherit-
ing the condition were identified. Involvement of patients
and their family members in the surveillance and screening
programmes is shown in Fig 1. The colorectal phenotypes
of the 108 patients with FAP are shown in Fig 2. Thirty-one
patients were diagnosed with FAP by the Registry screen-
ing programme. The median age at diagnosis was 34.0 years
(range, 12.0-69.0 years; SD, 14.1 years). Patients diagnosed
by screening were, however, significantly younger than
those diagnosed due to colorectal symptoms (median age,
29.0 years; SD, 15.2 years against median age, 36.0 years;
SD, 13.3 years; P=0.002). Fifty (46.3%) patients developed
colorectal cancer: 47 were diagnosed when the patients
presented with symptoms, and three were diagnosed during
the screening process. In other words, 61.0% of patients
with FAP had already developed colorectal cancer by the
time they presented with symptoms. However, only 9.7%
of them had already developed colorectal malignancy when
FAP was diagnosed by screening. Among these 50 patients,
four (8.0%) also had multicentric cancers. The median
age at colorectal cancer diagnosis was 40.0 years (range,
24.0-65.0 years; SD, 12.7 years). There was no difference
between male and female patients regarding the age at
FAP diagnosis, the rate of colorectal cancer, and the age at
colorectal cancer diagnosis.
36 families
18 <12 years old 159 ≥12 years old
177 at-risk family members
Pedigree analysis
77 patients with familial adenomatous
polyposis diagnosed by symptoms
45 alive at
recruitment
defer screening
(10.2%)
32 died before
recruitment
39 entered surveillance programme*
4 resided outside Hong Kong
2 refused recruitment
31 diagnosed with familial adenomatous polyposis*
37 discharged after genetic testing
44 continued to be screened†
16 (9.0%)
resided
elsewhere
112 (63.3%)
accepted
screening
31 (17.5%)
refused
screening
* 70 patients with familial adenomatous polyposis had treatment and surveillance data available for detailed study
† Reasons: genetic testing was not possible (no surviving index patient); mutation could not be found; or waiting for results of genetic testing
Fig 1. Flowchart showing the involvement of patients and at-risk family members in the surveillance and screening programmes
* CRC colorectal cancer
† Six not recruited (2 male, 4 female)
Fig 2. Flowchart outlining the colorectal phenotype of the 108 patients with familial adenomatous polyposis
77 diagnosed by symptoms
(44 male, 33 female)
31 diagnosed by screening
(15 male, 16 female)
108 patients with familial adenomatous polyposis
(59 male, 49 female)
8 alive
(4 male, 4 female)
47 with CRC*
(28 male, 19 female)
30 without CRC†
(16 male, 14 female)
3 with CRC
(1 male, 2 female)
28 without CRC
(14 male, 14 female)
32 died before
recruitment
(20 male, 12 female)
7 died after
recruitment
(4 male, 3 female)
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Two patients were initially diagnosed to have FAP when
they were screened 8 and 22 years previously. However,
they refused prophylactic colectomy only to present later
with colorectal cancer symptoms. At the time of this survey,
one of these patients had already died from meta-
static disease. In another patient, a stage IV rectal cancer
developed 1 year after total abdominal colectomy (IRA) at
another hospital. The patient later died from metastatic
disease. Up to July 2001, 39 patients had died from colorectal
cancer, giving an overall colorectal cancer mortality rate of
78.0%. For those colorectal cancer patients diagnosed
based on symptoms, the colorectal cancer mortality rate was
83.0%.
Among the 108 patients with FAP, 70 (37 male and
33 female) were recruited to the Registry. Therefore, more
detailed clinical and surveillance data were available from
these individuals for further analysis. To date, 52 of these
patients have already received surgery for large bowel
polyposis. This includes 34 prophylactic operations and
18 operations for colorectal malignancy. The types of
operation performed are shown in Table 1. Among these 52
patients, 40 (76.9%) received sphincter-saving procedures,
including 12 (66.7%) procedures for colorectal cancer
and 28 (82.4%) procedures for cancer prophylaxis. At
the time of writing, 15 newly diagnosed patients with
FAP were awaiting further examination before preventive
surgery. Three patients refused to have an operation. Apart
from colorectal cancer, four female patients with FAP
from different families developed papillary thyroid cancer
at the ages of 18, 20, 22, and 23 years. All these cancers
were diagnosed before the clinical diagnosis of FAP was
made. The median interval between thyroid cancer and
FAP diagnosis was 5.0 years (range, 1.0-19.0 years; SD,
8.1 years). Eleven (5 male, 6 female) patients had desmoid
tumours. One patient developed an extra-abdominal desmoid
tumour (over the pubic region) before colorectal resection,
the remaining 10 developed desmoid tumours after surgery.
The median interval between colorectal resection and
desmoid tumour diagnosis was 2.0 years (range, 1.0-18.0
years; SD, 5.1 years). The sites of the desmoid tumours are
shown in Table 2. The median age at desmoid tumour
diagnosis was 33.0 years (range, 21.0-43.0 years; SD, 7.5
years). Three patients with abdominal wall desmoid tumours
underwent surgical excision without recurrence. The two
extra-abdominal desmoid tumours (one over the pubic
region and the other on the back) were also excised with-
out recurrence. One patient with tumours on both the abdom-
inal wall and inside the peritoneal cavity underwent excision
of the abdominal wall component. Another patient under-
went a debulking procedure of the abdominal wall
component. All three patients with intra-abdominal desmoid
tumours were medically treated.
At surveillance upper endoscopy, four patients (1 male
and 3 female) were found to have duodenal adenomas. The
median age at diagnosis was 43.0 years (range, 30.0-67.0
years; SD, 16.0 years). The median interval from colectomy
was 11.5 years (range, 1.0-34.0 years; SD, 14.6 years). One
patient who had a single pedunculated adenoma underwent
endoscopic polypectomy. The remaining three had mul-
tiple polyps and were expectantly treated. No ampullary
adenocarcinoma has been diagnosed in the patients so far.
One patient was found to have adenomas at the antral
region of the stomach. Fundic gland polyposis was found
in 18 (25.7%) patients at a median age of 32.0 years
(range, 14.0-52.0 years; SD, 11.4 years). During surveil-
lance duodenoscopy, the periampullary region was routinely
biopsied to look for dysplastic changes, although no gross
polyps were identified. In 12 (17.1%) patients (6 male, 6
female), microscopic adenomatous changes were identified
in the periampullary region at a median age of 35.0 years
(range, 21.0-47.0 years; SD, 8.7 years). Such changes were
found at a median interval of 5.0 years (range, 0-18.0 years;
SD, 5.9 years) after colectomy. Among the 23 patients
with pelvic pouches, pouch polyposes were found in four
(17.4%) individuals (2 male, 2 female) at surveillance
pouchoscopy. The median age at diagnosis of pouch poly-
posis was 33.0 years (range, 29.0-38.0 years; SD, 4.0 years).
Pouch polyposis occurred at a median interval of 11.5 years
(range, 7.0-15.0 years; SD, 3.9 years) after restorative
proctocolectomy.
Discussion
This is the first paper on the phenotypic spectrum and
clinical management of FAP in Chinese patients in Hong
Kong. Familial adenomatous polyposis is a rare yet com-
plex condition that poses challenging management issues
to clinicians. By compiling clinical data through a dedicated
registry, we hope that enough information can be obtained
Table 1. Types of surgical resection performed
Surgical resection For cancer For prophylaxis Total
Proctocolectomy and ileal pouch anal anastomosis 6 17 23
Total abdominal colectomy and ileorectal anastomosis 5 9 14
Koch pouch 0 1 1
End ileostomy 4 5 9
Others* 3 2 5
* These included two Hartmann’s procedures and one right hemicolectomy for cancer palliation, one proctocolectomy and straight ileal-anal anastomosis, and
one unknown procedure for prophylaxis
Table 2. Sites of desmoid tumour
Desmoid tumour No. of patients
Intra-abdominal 3
Abdominal wall 4
Extra-abdominal 2
Combined* 2
* Intra-abdominal and abdominal wall
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to provide insights into the treatment of this rare colorectal
cancer syndrome.
Based on the estimated worldwide population frequency
of 1 in 10 000,1 there should be at least 700 patients with
FAP in Hong Kong. However, the number of patients
enrolled by the Registry, which is the largest in Hong Kong,
is much lower than this estimate. Even if the second largest
collection by another university hospital in Hong Kong is
added, the total number of local patients still falls short of
the estimation. Whether the current number represents gross
underdiagnosis of the condition or true lower incidence
than in other parts of the world can only be answered by a
population study. The reported spontaneous mutation rate
for FAP varies from 10% to 30%.9 The local rate of 41.7%
is high, which may be due to ascertainment bias or a truly
higher mutation rate than in other population groups.
Although FAP is a deleterious dominant condition with dire
consequences for the affected patients, the selective dis-
advantage associated with the presence of the mutation
is equal to the frequency of new mutation.10 As a result,
this condition is maintained in the population by such a
mutation-selection balance. As expected, patients with FAP
diagnosed by screening are significantly younger than those
diagnosed as a result of bowel symptoms. This may explain
why the incidence of colorectal cancer in those diagnosed
by symptoms was much higher than that in those diagnosed
by screening. The median age at colorectal cancer diagno-
sis for the patients in this study was similar to previous
reports.11,12 The colorectal cancer mortality in the patients
was high, which supports the view that presymptomatic diag-
nosis by screening followed by appropriate prophylactic
surgery are effective ways to prevent colorectal cancer and
its associated mortality in families with FAP.
All patients with FAP require surgical therapy for
colorectal polyposis. Prophylactic surgery should be per-
formed shortly after the clinical diagnosis is established by
endoscopy. The objectives of prophylactic surgery are to
remove all at-risk colorectal mucosa as well as to maintain
a continent and low frequency anal evacuation.11 The
colorectal phenotype, particularly the number of rectal
adenomas and the coexistence of cancer, is the main deter-
minant for the most appropriate surgical procedure to be
performed. Other factors for consideration are anal sphinc-
ter function, site of adenomatous polyposis coli (APC) gene
mutation,13 personal or family history of desmoid tumour,
and the feasibility of close endoscopic surveillance.
Colorectal resections of the patients in this study were per-
formed by a number of local surgeons over a span of 38
years. The first proctocolectomy and ileal pouch anal
anastomosis (IPAA) in Hong Kong was performed in 1984.
Since that time, IPAA has become the most commonly used
surgical procedure. Over the years, there has been an
increasing use of the sphincter-saving procedure as the
surgical treatment of choice for cancer therapy as well as
prophylaxis. The only exception is bulky and/or low rectal
cancer for which proctocolectomy and end-ileostomy is the
only feasible treatment. The appropriate choice of surgical
procedure is important for achieving colorectal cancer
prevention. For the patient who died of metastatic rectal
cancer shortly after IRA, it is apparent that IPAA instead
of IRA should have been the surgical procedure because of
the extent of rectal polyposis. However, for patients with
limited rectal polyposis who are willing to undergo lifelong
endoscopic surveillance every 6 months and ablation of
rectal polyps, IRA can be a suitable surgical option.11
Extracolonic manifestations can be a cause of morbid-
ity and later mortality for FAP patients.10 Papillary thyroid
cancer is reported to affect 1% to 2% of patients with
FAP,14 but the rate for the Registry was high at 5.7%.
Similar to the experience of the Registry, papillary thyroid
cancer showed female predominance.15 The reported mean
age at thyroid cancer diagnosis was 34 years15 whereas the
patients in this study were much younger. Similar to the
sporadic form, the prognosis of FAP-associated papillary
thyroid cancer is good. Desmoid tumour affects 10% to
17% of patients with FAP.11,16,17 Despite being slow grow-
ing with no metastatic potential, desmoid tumours can cause
significant morbidity and mortality due to their ability to
surround, compress, and erode adjacent structures.11 Among
the patients in this study, enterocutaneous fistula and ur-
eteric obstruction with hydronephrosis were the observed
complications. Predisposed by surgical trauma, up to 85%
of abdominal desmoid tumours were reported to develop
within 5 years of abdominal procedures.11 Extra-abdominal
and abdominal wall desmoid tumours can usually be resected
with good outcomes. However, attempts at resection of an
intra-abdominal desmoid tumour are often fraught with
difficulty, in that there is significant risk of bowel injury as
well as a high recurrence rate. Therefore, medical treatment
is often adopted unless complications occur.
The remaining gastrointestinal tract is also at risk of
adenomatous change and malignant transformation. After
prophylactic colectomy, patients with FAP should continue
to have lifelong regular surveillance for the remaining
at-risk gastrointestinal mucosa.18 Gastric and duodenal
adenomas have been reported to occur in 44% to 91% of
patients19 with duodenal adenomas usually occurring 10 to
20 years after development of colorectal polyposis.11 The
incidence of duodenal carcinoma in FAP is between 1% and
5%,11 and it accounts for the largest number of cancer-
related deaths in patients with FAP after colectomy.20,21 Due
to the short follow-up period and the relatively young age
of the five patients with gastroduodenal adenoma, no malig-
nant transformation has been detected so far. The patients
in this study with duodenal microadenoma were younger
than those with gross gastroduodenal adenomas. Whether
these duodenal microadenomas will develop into gross
adenoma and whether they have malignant potential remain
unknown. Only long-term follow-up can determine the
outcome of these microadenomas. It is increasingly recog-
nised that polyposis can develop in the pelvic pouches after
IPAA22,23 with a theoretical risk of malignant transformation.
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The growth defect conferred by APC gene mutation, the
altered surgical anatomy, and faecal stasis in the pouch
are contributory factors for pouch adenomatous change.21
Upon identification, pouch adenoma can be controlled
using a combination of endoscopic ablation and sulindac
treatment.21,24 The efficacy of endoscopic surveillance for
the remaining gastrointestinal tract is unknown. However, a
decision analysis by Vasen et al25 for the management of
duodenal polyposis suggested that regular surveillance
resulted in an increased life expectancy of patients with
FAP.
Clinical management of families with a complex heredi-
tary colorectal cancer syndrome of FAP requires a
multidisciplinary approach. Vigilant and lifelong surveil-
lance of these individuals can be demanding from an
administrative perspective. Therefore, coordination by a
dedicated regional registry with its concentrated expert-
ise and resources is important.18 Clinical management of
affected families by regional registry has led to improve-
ment in life expectancy of patients with FAP.2,26-28 From
analysis of the data obtained from 36 Chinese families
with FAP in Hong Kong, presymptomatic diagnosis by
screening followed by appropriate prophylactic surgery are
effective ways to prevent colorectal cancer in these high-
risk individuals. Apart from colorectal polyposis and cancer,
patients with FAP are also prone to develop a number of
ECMs with potentially serious consequences. Therefore,
lifelong regular surveillance is necessary to detect and to
manage these ECMs. Clinical management of families with
FAP can best be coordinated by a dedicated registry.
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